Global Granulocyte Macrophage Colony Stimulating Factor Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Granulocyte Macrophage Colony Stimulating Factor Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Granulocyte Macrophage Colony Stimulating Factor report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Granulocyte Macrophage Colony Stimulating Factor market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Solid Tumor and Lymphoma are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Granulocyte Macrophage Colony Stimulating Factor industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Granulocyte Macrophage Colony Stimulating Factor key manufacturers include Aduro BioTech Inc, Amgen Inc, BriaCell Therapeutics Corp, Cold Genesys Inc, GlaxoSmithKline Plc, Humanigen Inc, Mologen AG, Morphotek Inc and Sillajen Biotherapeutics, etc. Aduro BioTech Inc, Amgen Inc, BriaCell Therapeutics Corp are top 3 players and held % sales share in total in 2022.
Granulocyte Macrophage Colony Stimulating Factor can be divided into CG-0070, Gimsilumab, GSK-3196165 and Lenzilumab, etc. CG-0070 is the mainstream product in the market, accounting for % sales share globally in 2022.
Granulocyte Macrophage Colony Stimulating Factor is widely used in various fields, such as Solid Tumor, Lymphoma, Kidney Cancer and Lung Disease, etc. Solid Tumor provides greatest supports to the Granulocyte Macrophage Colony Stimulating Factor industry development. In 2022, global % sales of Granulocyte Macrophage Colony Stimulating Factor went into Solid Tumor filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Granulocyte Macrophage Colony Stimulating Factor market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Aduro BioTech Inc
Amgen Inc
BriaCell Therapeutics Corp
Cold Genesys Inc
GlaxoSmithKline Plc
Humanigen Inc
Mologen AG
Morphotek Inc
Sillajen Biotherapeutics
Takeda Pharmaceutical Co Ltd
Segment by Type
CG-0070
Gimsilumab
GSK-3196165
Lenzilumab
MGN-1601
Others
Solid Tumor
Lymphoma
Kidney Cancer
Lung Disease
Others
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Granulocyte Macrophage Colony Stimulating Factor market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Granulocyte Macrophage Colony Stimulating Factor, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Granulocyte Macrophage Colony Stimulating Factor industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Granulocyte Macrophage Colony Stimulating Factor in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Granulocyte Macrophage Colony Stimulating Factor introduction, etc. Granulocyte Macrophage Colony Stimulating Factor Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Granulocyte Macrophage Colony Stimulating Factor market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
North America, Europe and Asia Pacific are the key regions for Granulocyte Macrophage Colony Stimulating Factor industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Granulocyte Macrophage Colony Stimulating Factor key manufacturers include Aduro BioTech Inc, Amgen Inc, BriaCell Therapeutics Corp, Cold Genesys Inc, GlaxoSmithKline Plc, Humanigen Inc, Mologen AG, Morphotek Inc and Sillajen Biotherapeutics, etc. Aduro BioTech Inc, Amgen Inc, BriaCell Therapeutics Corp are top 3 players and held % sales share in total in 2022.
Granulocyte Macrophage Colony Stimulating Factor can be divided into CG-0070, Gimsilumab, GSK-3196165 and Lenzilumab, etc. CG-0070 is the mainstream product in the market, accounting for % sales share globally in 2022.
Granulocyte Macrophage Colony Stimulating Factor is widely used in various fields, such as Solid Tumor, Lymphoma, Kidney Cancer and Lung Disease, etc. Solid Tumor provides greatest supports to the Granulocyte Macrophage Colony Stimulating Factor industry development. In 2022, global % sales of Granulocyte Macrophage Colony Stimulating Factor went into Solid Tumor filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Granulocyte Macrophage Colony Stimulating Factor market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Aduro BioTech Inc
Amgen Inc
BriaCell Therapeutics Corp
Cold Genesys Inc
GlaxoSmithKline Plc
Humanigen Inc
Mologen AG
Morphotek Inc
Sillajen Biotherapeutics
Takeda Pharmaceutical Co Ltd
Segment by Type
CG-0070
Gimsilumab
GSK-3196165
Lenzilumab
MGN-1601
Others
Segment by Application
Solid Tumor
Lymphoma
Kidney Cancer
Lung Disease
Others
Segment by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Granulocyte Macrophage Colony Stimulating Factor market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Granulocyte Macrophage Colony Stimulating Factor, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Granulocyte Macrophage Colony Stimulating Factor industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Granulocyte Macrophage Colony Stimulating Factor in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Granulocyte Macrophage Colony Stimulating Factor introduction, etc. Granulocyte Macrophage Colony Stimulating Factor Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Granulocyte Macrophage Colony Stimulating Factor market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices